×
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:CERE

Cerevel Therapeutics Stock Forecast, Price & News

$28.15
-0.48 (-1.68%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.81
$29.34
50-Day Range
$20.62
$33.27
52-Week Range
$12.50
$46.16
Volume
1.80 million shs
Average Volume
472,454 shs
Market Capitalization
$4.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00
30 days | 90 days | 365 days | Advanced Chart

Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CERE Stock Forecast (MarketRank)

Overall MarketRank

1.84 out of 5 stars

Medical Sector

745th out of 1,418 stocks

Pharmaceutical Preparations Industry

362nd out of 679 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
Cerevel Therapeutics logo

About Cerevel Therapeutics (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Coal & Consumable Fuels
Sector
Medical
Current Symbol
NASDAQ:CERE
CUSIP
15677310
Fax
N/A
Employees
200
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/24/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$41.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+45.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$-225.33 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.92 per share

Miscellaneous

Free Float
142,951,000
Market Cap
$4.17 billion
Optionable
Not Optionable
Beta
2.79














Cerevel Therapeutics Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Cerevel Therapeutics stock.
View analyst ratings for Cerevel Therapeutics
or view top-rated stocks.

What is Cerevel Therapeutics' stock price forecast for 2022?

6 Wall Street research analysts have issued 1-year target prices for Cerevel Therapeutics' shares. Their CERE stock forecasts range from $20.00 to $50.00. On average, they anticipate Cerevel Therapeutics' share price to reach $41.00 in the next twelve months. This suggests a possible upside of 45.6% from the stock's current price.
View analysts' price targets for Cerevel Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Cerevel Therapeutics' stock performed in 2022?

Cerevel Therapeutics' stock was trading at $32.42 at the beginning of the year. Since then, CERE stock has decreased by 13.2% and is now trading at $28.15.
View the best growth stocks for 2022 here
.

When is Cerevel Therapeutics' next earnings date?

Cerevel Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Cerevel Therapeutics
.

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.02. During the same period in the prior year, the firm earned ($0.40) earnings per share.
View Cerevel Therapeutics' earnings history
.

Who are Cerevel Therapeutics' key executives?

Cerevel Therapeutics' management team includes the following people:
  • Dr. N. Anthony Coles Jr., M.P.H., CEO & Exec. Chairman (Age 62, Pay $1.24M)
  • Dr. John J. Renger Ph.D., Chief Scientific Officer (Age 53, Pay $945.08k)
  • Ms. Kathleen Tregoning M.A., Chief Corp. Affairs Officer (Age 51, Pay $600.79k)
  • Mr. Abraham N. Ceesay M.B.A., Pres (Age 44)
  • Mr. Mark Bodenrader, Interim CFO, VP of Fin. & Chief Accounting Officer (Age 49)
  • Mr. Matthew Calistri, VP of Investor Relations
  • Mr. Scott M. Akamine J.D., Chief Legal Officer (Age 38)
  • Mr. Kenneth A. DiPietro, Chief HR Officer (Age 63)
  • Dr. Ramiro Sanchez, Chief Medical Officer (Age 61)

Who are some of Cerevel Therapeutics' key competitors?

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).

What is Cerevel Therapeutics' stock symbol?

Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE."

Who are Cerevel Therapeutics' major shareholders?

Cerevel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.25%), BlackRock Inc. (2.29%), State Street Corp (1.46%), Rock Springs Capital Management LP (1.16%), Lord Abbett & CO. LLC (0.49%) and Northern Trust Corp (0.28%). Company insiders that own Cerevel Therapeutics stock include Gabrielle Sulzberger, John Renger and Perceptive Advisors Llc.
View institutional ownership trends for Cerevel Therapeutics
.

Which major investors are selling Cerevel Therapeutics stock?

CERE stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., UBS Group AG, Affinity Asset Advisors LLC, Citigroup Inc., BlackRock Inc., State Street Corp, JPMorgan Chase & Co., and Bank of New York Mellon Corp.
View insider buying and selling activity for Cerevel Therapeutics
or view top insider-selling stocks.

Which major investors are buying Cerevel Therapeutics stock?

CERE stock was bought by a variety of institutional investors in the last quarter, including Ally Bridge Group NY LLC, Candriam Luxembourg S.C.A., Woodline Partners LP, Alyeska Investment Group L.P., The Manufacturers Life Insurance Company , Verition Fund Management LLC, Verition Fund Management LLC, and Rock Springs Capital Management LP. Company insiders that have bought Cerevel Therapeutics stock in the last two years include Gabrielle Sulzberger, and Perceptive Advisors Llc.
View insider buying and selling activity for Cerevel Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cerevel Therapeutics?

Shares of CERE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerevel Therapeutics' stock price today?

One share of CERE stock can currently be purchased for approximately $28.15.

How much money does Cerevel Therapeutics make?

Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $4.17 billion. The biotechnology company earns $-225.33 million in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Cerevel Therapeutics have?

Cerevel Therapeutics employs 200 workers across the globe.

How can I contact Cerevel Therapeutics?

Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for Cerevel Therapeutics is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at [email protected].

This page (NASDAQ:CERE) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.